FGFR2 Gene Mutation clinical trials at UCSF

1 research study open to eligible people

The FGFR2 gene controls cell growth, and when it mutates it can cause cancer. UCSF is recruiting patients for a clinical trial studying a new drug called RLY-4008 to treat advanced solid tumors, focusing on bile duct cancer. The study will check the safety and effectiveness of RLY-4008.

Showing trials for

  • REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

    open to eligible people ages 18 years and up

    This is a Phase 1/2, open-label, FIH study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDy), and antineoplastic activity of RLY-4008, a potent and highly selective FGFR2 inhibitor, in patients with unresectable or metastatic cholangiocarcinoma (CCA) and other solid tumors. The study consists of 3 parts: a dose escalation (Part 1), a dose expansion (Part 2), and an extension (Part 3).

    San Francisco, California and other locations

Last updated: